What changed: Hepatoblastoma
Every dated change on the records linked to Hepatoblastoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Guideline1Milestone7This record1
September 2026 · 1
2018 · 1
2017 · 1
2013 · 2
- 2013GuidelineHepatoblastomaGuideline PHITT / SIOPEL-3 (Lancet Oncol 2013); SIOPEL-6 (NEJM 2018): Very low / standard risk (PRETEXT I-III, resectable, AFP >100)
Upfront resection for PRETEXT I-II (COG) or cisplatin monotherapy ×4-6 with delayed resection (SIOPEL-3); sodium thiosulfate after each cisplatin dose for otoprotection.
- 2013MilestoneCisplatinSIOPEL-4: dose-dense cisplatin in high-risk disease (Lancet Oncol)
A milestone in how this cancer is treated.